NASDAQ:IMUX Immunic Q3 2026 Earnings Results & Report $7.77 -0.02 (-0.24%) As of 12:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Immunic missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.99 versus the -$0.7852 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Immunic EPS ResultsActual EPS-$0.99Consensus EPS -$0.7852Beat/MissMissed by -$0.2048One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersImmunic Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunic Q3 2026 Earnings FAQ Did Immunic beat earnings estimates for Q3 2026? Immunic (NASDAQ:IMUX) reported earnings of -$0.99 per share for Q3 2026, missing the consensus estimate of -$0.7852. The report was announced on Friday, November 13, 2026. Immunic Earnings HeadlinesImmunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 20262 hours ago | rttnews.comImmunic (IMUX) Q3 2026 Results: Everything Hinges on December MS Data2 hours ago | 247wallst.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts2 hours ago | finance.yahoo.comWhy is Immunic stock falling 5% following its third-quarter results?2 hours ago | msn.comImmunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 13 at 6:30 AM | prnewswire.comSee More Immunic Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email. Email Address About ImmunicImmunic (NASDAQ:IMUX) is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases. Immunic has operations in the United States and Germany. Its products remain investigational, and the company does not currently market an approved therapy.View Immunic ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
